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Before the success story of leukaemia treatment started in the 
1950s, many patients succumbed to the disease because of severe 
haemorrhage. A bleeding tendency is one of the hallmarks of 
haematological malignancies such as leukaemia, since together with 
anaemia and an increased susceptibility to infection it completes the 
picture of bone marrow failure. Almost half of patients with acute 
lymphoblastic leukaemia present with bleeding.1 It can also become 
evident when the bone marrow is infiltrated by a non-haematological 
malignancy, e.g. neuroblastoma. Thus, easy bruising is one of the St 
Siluan early warning signs of childhood cancer, compiled by the South 
African Children’s Cancer Study Group (SACCSG). An increased 
risk of bleeding during the cancer treatment period is almost always 
present, due to the bone marrow suppressive effect of chemotherapy. 
Fortunately, death due to bleeding is rare these days.  
His tory and clinical picture 
When evaluating a child with a possible bleeding tendency, one 
should always distinguish between a mucocutaneous and a clotting 
factor deficiency bleeding pattern. The mucocutaneous pattern is a 
superficial bleeding, such as epistaxis, petechiae and ecchymoses (Fig. 
1) and the clotting factor deficiency bleeding is haemarthroses and 
deep-muscle haematomas. If the child is very well and has no other 
symptoms or signs suggestive of a more sinister disease, a congenital 
bleeding tendency should be considered. 
In a child with cancer, however, the history usually reveals a relatively 
short period of increased bruising or recurrent episodes of bleeding in 
a child who is unwell. Sometimes the patient or mother will report that 
bruising occurred without trauma and in areas not normally involved in 
trauma-related bruises, e.g. peri-orbital bruising. Recurrent infections, 
infections not responding to appropriate therapy, fatigue, weight loss, 
bone pain and pallor are some of the other symptoms that may also be 
reported, indicating a haematological malignancy.
On examination a petechial or purpuric rash is often present when 
the platelet count is <20x109/l.  Overt bleeding from the oral mucosa, 
nose and rectum may occur, as well as haematuria. Intracranial 
haemorrhage is sometimes present at diagnosis and can of course be 
catastrophic. A rare presenting symptom in children with leukaemia, 
called leukaemia cutis, may be confused with ecchymoses, since the 
lesions may be purplish in colour. The difference is that leukaemia cutis 
characteristically has nodules that are palpable and non-tender. The 
lesions may be colourless, blue or light purple. Other signs to be looked 
for are lymphadenopathy, hepatosplenomegaly and other masses. 
Causes and pathoph ysiology of bleeding 
(Table I))
Bleeding at presentation is most commonly caused by bone marrow 
infiltration, whether by the primary haematological malignancy or by 
metastatic infiltration of a non-haematological malignancy. Proliferation 
of malignant cells in the bone marrow displaces normal haemopoietic 
precursor cells, leading to a decrease in haemopoietic precursor cells 
and peripheral cytopenias, ranging from a single cell line affected to 
pancytopenia. The most common cause is acute lymphoblastic leukaemia, 
where the normal bone marrow is being replaced by leukaemic blasts. 
In metastatic Hodgkin’s and non-Hodgkin’s lymphomas bone marrow 
infiltration may be present. Neuroblastoma and rhabdomyosarcoma 
are examples of solid tumours that can cause non-haematological 
infiltration of the bone marrow. Metastatic neuroblastoma typically 
leads to the development of `raccoon eyes’ (periorbital ecchymoses due 
to local periorbital infiltration and probable obstruction of the palpebral 
blood vessels) (Fig. 2). 
Certain characteristics of the malignant cells themselves can trigger 
bleeding. Acute myeloid leukaemia (AML) notoriously can cause severe, 
life-threatening bleeding. Thrombocytopenia is commonly present, 
but a coagulopathy can also occur due to proteins with anticoagulant 
activity being released by the leukaemic blasts. Disseminated 
intravascular coagulopathy (DIC) is most frequently seen with acute 
promyelocytic leukaemia (AML M3), since the promyelocytes contain 
a high number of these granules. These blasts also express annexin II, 
which activates plasminogen. DIC triggered by infection may also be 
present in other malignancies at the time of presentation.   
Cancer treatment regularly causes bleeding, since almost all 
chemotherapy agents cause bone marrow suppression, and therefore 
thrombocytopenia, but bleeding is also secondary to DIC in a few 
cases. The degree of suppression is dependent on treatment dose, the 
number of treatment courses the patient has already received, as well as 
individual reactions. The nadir of the platelet count is usually reached 
7 - 10 days after chemotherapy, except in the case of carboplatinum/
cisplatinum, where prolonged thrombocytopenia is often seen. 
L-asparaginase, which is used in the treatment of leukaemia, can cause 
coagulopathy due to a decrease in antithrombin III and fibrinogen. 
Radiotherapy, when it involves a large field, also causes bone marrow 
suppression, including thrombocytopenia.
Peripheral destruction of platelets can occur in episodes of febrile 
neutropenia (fever in the presence of a neutrophil count <0.5x109/l). 
Bleeding in children with cancer 
Bleeding is characteristic of many types and stages of childhood  
cancer.
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Proph ylactic platelet 
transfusions
Prophylactic platelet transfusions are 
administered with the aim of reducing the 
risk of severe bleeding in children with 
cancer.3 However, the jury is still out on 
whether prophylactic transfusions truly 
are necessary for patients with chronic 
thrombocytopenia without additional risk 
factors to prevent haemorrhage or whether 
it would be safe and effective to transfuse 
platelets only in the event of bleeding. Since 
1966, when a study reported a significant 
decrease in the number of haemorrhagic 
deaths in children with leukaemia after the 
implementation of a prophylactic transfusion 
programme, clinicians have been prescribing 
prophylactic platelet transfusions. In 2006 it 
was reported that platelet transfusions were 
administered only when bleeding occurred in 
adult autologous stem cell transplant patients 
and that this approach was safe.2 No recent 
randomised control trials implementing 
the lower platelet transfusion threshold in 
children have explored this issue. Currently 
all paediatric oncology units still employ 
prophylactic platelet transfusions since 
authoritative organisations still advocate 
prophylactic treatment.3,4 
Platelet transfusions are very expensive 
and have several side-effects. It is therefore 
important to adhere strictly to transfusion 
guidelines so as to balance the risk versus 
benefit see-saw. Guidelines as to the 
transfusion threshold have become more 
conservative and currently suggest platelet 
transfusion for a platelet count less than 
10 x 109/l in a patient without additional 
risk factors for bleeding.3-8  A Cochrane 
review has concluded that there was no 
statistical difference in mortality, remission 
rate, number of severe bleeding episodes or 
red cell transfusion requirements between 
patients where a cut-off value of 10 x 109/l 
and patients where 20 x 109/l was used.8 It 
was unclear though whether the studies had 
sufficient power to demonstrate that the 
lower threshold was safe. There is a paucity 
of evidence-based guidelines in children, 
but the available guidelines also advocate 
the use of the lower transfusion threshold of 
<10x109/l in a low-risk setting.4
Several clinical factors need to be taken 
into account when considering platelet 
transfusion, and if any of the following 
are present one should have a lower 
threshold for ordering a platelet transfusion 
(<20x109/l): sudden drop in platelet count, 
previous life-threatening bleeding, severe 
anaemia, fever, infection, DIC, liver disease, 
disease factors (e.g. AML M3 causing 
coagulopathy) and medication that could 
exacerbate bleeding. The phase of therapy and 
the risk of allo-immunisation (development 
of antibodies to donor proteins) should also 
be considered.  The availability of platelets 
and how rapidly they could be sourced is 
an important factor to take into account.3 
Allo-immunisation has been shown to 
adversely affect outcome in certain patients, 
e.g. patients eligible for a bone marrow 
transplant,9 so it is important to keep the 
number of transfusions as low as possible. 
For most surgical procedures a platelet 
count of >50x109/l is sufficient, provided 
no additional risk factors are present.3,5,6  A 
count of  >100x109/l is required for major 
surgery and any neurosurgical procedure.5,6 
Bone marrow aspiration and biopsy can be 
performed safely even in the presence of 
severe thrombocytopenia, provided adequate 
pressure is applied to the puncture sites.3 Prior 
to intrathecal administration of chemotherapy 
it must be ensured that the platelet count is 
>20x109/l.4  For a diagnostic lumbar puncture 
in a patient with leukaemia a higher count of 
>100x109/l is required to minimise the risk 
of bleeding and introducing blasts into the 
cerebrospinal fluid.10,11  The generally accepted 
platelet transfusion threshold for neonates is 
<30x109/l.12
There are good evidence-based guidelines 
for platelet transfusion thresholds in 
different situations, but the limitations must 
be taken into account, namely that data are 
extrapolated from studies on adults, doctors 
must be able to identify additional risk 
factors of bleeding in patients, and the lower 
thresholds can only be followed if platelets 
are readily available and patients are able to 
rapidly access medical services. A paediatric 
haematologist/oncologist should be consulted 
whenever there is doubt.
Therapeutic platelet 
transfusions
Therapeutic platelets are administered to 
stop active bleeding. The World Health 
Organization (WHO) has advised the 
following grading system for any patient 
with haemorrhage:13 
•    WHO grade 0:  none 
•    WHO grade 1: petechiae, ecchymosis, 
occult blood in body secretions, vaginal 
spotting
•    WHO grade 2: gross bleeding (e.g. 
epistaxis, haematuria, haematemesis) that 
does not require additional transfusion 
support
•    WHO grade 3: bleeding requiring ≥1 units 
of packed cells/day
•    WHO grade 4: life-threatening bleeding.
Grades 1 and 2 usually correlate with the 
degree of thrombocytopenia, while grades 3 
and 4 are often associated with additional risk 
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Thrombocytopenia secondary to: 
•   Bone marrow infiltration 
     •    Haematological malignancy, e.g. 
leukaemia, lymphoma
     •    Non-haematological malignancy, 
e.g. neuroblastoma, rhabdomyo-
sarcoma
•   Infection 
•    Disseminated intravascular coagu-
lopathy 
•   Chemotherapy 
•   Radiotherapy
Coagulopathy secondary to: 
•    Anticoagulant activity of the malig-
nant cells, e.g. AML
•    Disseminated intravascular coagu-
lopathy 
•    Hyperleukocytosis (white cell count 
>100x109/l)
•   Chemotherapy, e.g. L-asparaginase
Fig.  2. `Raccoon eyes’ in metastatic neu-
roblastoma (with thanks to the Tygerberg 
Children’s Tumour Registry).
Fig. 1. Ecchymoses on a patient’s arm (with 
thanks to the Tygerberg Children’s Tumour 
Registry).
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factors for bleeding, e.g. septicaemia. Thus not 
all bleeding episodes of grades 3 and 4 may 
be controlled only by a platelet transfusion.6 
Therapeutic platelet transfusions are usually 
indicated for bleeding ≥WHO grade 2.6
Complications of platelet 
transfusion (Table II)5
Since platelet products are stored at 20 - 
24˚C rather than 4˚C as red cells are, the risk 
for transmission of bacteria is higher than 
with packed red cells.6 This is potentially 
lethal, but is fortunately unusual.  High-
quality tests currently used to exclude 
viral infections in donated platelets have 
decreased the risk of transmission to a very 
low level. Allo-immunisation (the formation 
of antibodies to donor proteins) can occur 
in three situations: in the event of ABO 
incompatibility, Rhesus incompatibility or 
when the patient is exposed to platelets that 
have not undergone leucocyte reduction and 
HLA antibodies are formed. The development 
of allo-immunisation causes the patient to 
be refractory to platelet transfusion. This 
can also be caused by non-immune factors, 
namely splenomegaly, drugs (ciprofloxacin, 
vancomycin, amphotericin, heparin), fever 
and infection, bleeding and DIC. It can be 
diagnosed when there is a poor response after 
transfusion on two subsequent occasions. 
Other immune-mediated complications 
include allergic reactions, febrile reactions, 
transfusion-related acute lung injury 
(TRALI), graft-versus-host disease (GVHD), 
anaphylaxis and haemolysis.
Management of a 
bleeding episode
The first priority is rapid assessment of 
the haemodynamic status of the patient 
(including clinical assessment and a side-
room haemoglobin determination) and 
appropriate resuscitation when necessary. 
Gross bleeding should be controlled by 
local measures. The next step would be to 
gain as much knowledge about the patient’s 
diagnosis, treatment and medication as is 
possible. It is important to identify whether 
additional risk factors such as septicaemia are 
present. A decision about which product(s) to 
transfuse can then be taken.  The laboratory 
work-up should include a full blood count, 
a peripheral smear and a clotting profile 
in order to ascertain the haematological 
cause of the episode (thrombocytopenia 
v. DIC).  The peripheral smear provides 
important information: presence of blasts 
indicating relapse, fragments and other signs 
of DIC, signs of infection and to confirm 
thrombocytopenia if present on the full blood 
count. If the clotting profile is abnormal, 
DIC and drugs precipitating DIC should be 
considered, as well as disease-specific factors, 
e.g. coagulopathy caused by AML, and liver 
disease due to the malignancy or secondary 
to drugs.  Fresh frozen plasma (10 - 15 ml/
kg) is indicated for clotting abnormalities 
and cryoprecipitate should be administered 
in massive haemorrhage to supplement 
fibrinogen as well. 
Which platelet product is 
the best for my patient?
Two types of platelet products are available: 
random/pooled platelets (prepared from 4 
- 6 donors’ blood) and single-donor/mega 
unit/apheresis platelets (prepared from a 
single donor’s blood).  Both of these are 
available in infant (±50 ml) and adult (±300 
ml) sizes. Random platelets (pooled unit) 
roughly cost R3 800, while a single-donor 
unit costs about R5 150. Filtering effectively 
reduces the numbers of leucocytes in 
random/pooled platelets in order to 
decrease the risk of allo-immunisation, 
febrile reactions and the transmission of 
cytomegalovirus (CMV). This process of 
leucocyte reduction will further increase 
the cost by R830. Studies have shown that 
the two products are similar in terms of the 
post-transfusional rise in the platelet count, 
the haemostatic effect and platelet survival.3 
Irradiation is only indicated for patients 
receiving allogeneic stem cell transplants, 
patients receiving products from related 
donors and severely immunocompromised 
patients.
Single-donor platelets are indicated for 
patients where allo-immunisation and 
refractoriness have occurred. The ideal for 
patients with these complications would be 
HLA-matched platelets, but this is rarely 
available to most patients due to cost and 
genetic diversity. In practice, single-donor 
platelets are currently used when a patient is 
eligible for a stem cell transplant in order to 
limit the exposure of the patient to multiple 
donors. However, the TRAP study concluded 
that the risk for allo-immunisation was 
the same when random/pooled versus 
single-donor platelets were used.14 Further 
studies are needed to confirm this. In most 
treatment units this product will also be used 
when a patient has had multiple transfusion 
reactions. In all other situations filtered 
random platelets must be used. Random 
platelets are usually more readily available 
than single-donor platelets and in the event 
of severe haemorrhage would be the product 
of choice for any patient. The traditional dose 
of 10 - 15 ml/kg should serve as a guideline 
whether to order one or more of the infant 
units or alternatively to order an adult unit. 
Platelets should never be wasted, since the 
complete unit can be safely transfused.      
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Table II. Complications of 
platelet transfusion5
Infectious 
•   Human immunodeficiency virus 
•   Hepatitis B and C 
•   Cytomegalovirus 
•    Bacterial transmission, resulting in 
septicaemia or septic shock
Immunological 
•   Allo-immunisation: Rh, ABO, HLA 
•   Febrile reactions 
•    Transfusion-related acute lung 
injury (TRALI)
•   Anaphylaxis 
•   Graft-versus-host disease 
•   Hypotension 
•   Haemolysis
